Navigation Links
Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
Date:10/16/2007

SAN FRANCISCO, Oct. 16 /PRNewswire/ -- Sugammadex -- the novel selective relaxant binding agent (SRBA) being developed by Organon -- demonstrated a faster recovery from profound neuromuscular blockade as compared to neostigmine in the Phase III pivotal Signal trial.(1) In a second trial, named Spectrum, faster recovery from profound neuromuscular blockade compared to spontaneous recovery was demonstrated.(2) The pivotal Signal trial results were presented today at the 2007 annual meeting of the American Society of Anesthesiologists (ASA) taking place in San Francisco from October 13-17. The Spectrum trial results were presented on October 14.

The Signal trial compared the efficacy and safety of sugammadex and neostigmine/glycopyrrolate for the reversal of profound rocuronium (Zemuron(R)/ Esmeron(R)/Eslax(R)) induced neuromuscular blockade. The Spectrum trial compared the efficacy and safety of sugammadex for reversal of profound rocuronium-induced neuromuscular blockade with that of spontaneous recovery from succinylcholine-induced blockade.

"The Signal trial results are clinically significant for anesthesiologists during neuromuscular blockade management, as with sugammadex they will be able to have control when using any depth of rocuronium-induced neuromuscular, and be able to reverse the blockade rapidly at any moment they want, which is not possible with current treatments," said Professor James E. Caldwell, University of California, San Francisco and one of the lead Signal trial investigators.

Reversal agents are used during general anesthesia to reverse the effects of muscle relaxants, also called neuromuscular blocking agents (NMBAs). Reversal of neuromuscular blockade enables spontaneous breathing to recommence earlier which helps to get patients out of the operating room quicker, freeing up capacity and personnel to help additional patients. Adequate reversal reduces the risk of residual paralysis, which may cause a number of serio
'/>"/>

SOURCE Organon
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
2. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
3. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
4. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
5. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
6. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; ... Technology Small Business Technology Transfer Research (STTR) grant ... Infectious Diseases (NIAID), a division of the National ... novel human antibody therapeutics to combat Staphylococcus ... infections, including methicillin-resistant S. aureus (MRSA), ...
(Date:5/17/2013)... 17, 2013  Technology advances have had a ... with a constantly evolving communication environment, companies need ... communicating with internal executives. It is challenging, however, ... tactics and tools that are part of today,s ... study, Best Practices, LLC explores the various internal ...
(Date:5/17/2013)... Biotechnology Inc. ("Sony") today announced the launch of the new ... Sony will also be exhibiting its newly rebranded reagent portfolio. ... EC800 flow cytometer, and new SP6800 Spectral Analyzer will be ... held at the San Diego Convention ... May 20 - 22.  The 8-well strip ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2Sony Delivers New Technology for Science to CYTO 2013 2
... For years, homecare equipment providers have cited the many ramifications ... of power wheelchairs for beneficiaries.  It is the root cause of ... and it restricts access to power wheelchairs for patients.  But rarely, ... , , ...
... July 16 Human erythropoietin (EPO) is a potent ... spinal cord injury, and Parkinson,s disease. However, EPO drug development ... the blood-brain barrier (BBB). In acute stroke or brain injury, ... insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals ...
Cached Medicine Technology:Physician Outraged by Medicare Power Wheelchair Documentation Policy 2Physician Outraged by Medicare Power Wheelchair Documentation Policy 3Physician Outraged by Medicare Power Wheelchair Documentation Policy 4ArmaGen® Re-engineers Erythropoietin for Brain Penetration 2
(Date:5/20/2013)... Minn. Patients with inflammatory bowel disease (IBD) are ... cancer, report researchers at Mayo Clinic. Researchers found that ... for the disease. The findings were presented at the ... More than 1.5 million Americans have Crohn,s disease or ... bowel disease. Both conditions inflame the lining of the ...
(Date:5/20/2013)... ParentMagic, the creator of the best selling parenting book ... in the month of May 2013. In addition to 1-2-3 ... and anyone interested in learning more about ADD and ADHD. ... materials, ParentMagic offers DVDs and Audio of the 1-2-3 Magic ... and teacher editions. , Parents who have children in several ...
(Date:5/20/2013)... May 20, 2013 The latest initiative ... assist students who wish to take admission to leading ... will start from June 1, to guide students in ... for leading management colleges. , IMP has been ... IGNOU and other open universities for completing assignments and ...
(Date:5/20/2013)... B. E. Smith, the only ... providers, has been retained to lead a national ... Hospital in Oswego, N.Y. The top executive search ... has recently placed more than 900 healthcare executives ... 164-bed, Joint Commission-accredited, acute care facility offering a ...
(Date:5/20/2013)... 2013 When developing diet plans, many ... are taken into consideration to help patients discover the ... determined that there is a clear connection between certain ... science behind these studies and others when creating their ... study exploring the effect weight gain may have on ...
Breaking Medicine News(10 mins):Health News:ParentMagic Announces May Sale, 20% Off Entire Catalog of Best Selling Books 2Health News:IGNOU MBA Project Launches Workshop for MBA Aspirants 2Health News:Oswego Hospital Retains B. E. Smith to Recruit New COO 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Improved hCG Diet Helping Patient’s Control Eating Impulses 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Improved hCG Diet Helping Patient’s Control Eating Impulses 3
... Calif, Nov. 3 BioMarin Pharmaceutical,Inc. (Nasdaq: ... Morquio Clinical,Assessment Program (MorCAP) for patients with the ... Morquio A Syndrome. MorCAP is,designed to augment available ... function and other parameters in affected patients.,BioMarin expects ...
... Services Cited as Pivotal to ... Efficiency Statewide, NASHVILLE, Tenn., Nov. 3 Emdeon, ... for the healthcare industry,has been named the electronic data ... Association (MHA). Emdeon was selected,through a competitive bidding process ...
... Va., Nov. 3 "When my father was formally,diagnosed ... book,pamphlet, and newspaper article I could get my hands ... Conversation About Alzheimer,s" (published by,AuthorHouse -- http://www.authorhouse.com ). ... I told myself that once I knew the facts, ...
... its inaugural list of the top 100, ... a leading,provider of kidney care services for those ... named in the top 100 of Modern Healthcare,s,Best ... on the list, is,the only nationwide healthcare services ...
... Nov. 3 Sabin Robbins, a,75-year old prostate ... Florida to benefit from treatment with new RapidArc(TM),radiotherapy ... Cancer Center of Boynton Beach, Florida. RapidArc, which ... ), unleashes the precision of,intensity-modulated radiation therapy (IMRT) ...
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), ... novel anti-infective products, today,announced that it has ... VCG,& Associates will serve as MiddleBrook,s strategic ... pricing and reimbursement, contract,administration, national account management ...
Cached Medicine News:Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4Health News:Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange 2Health News:'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease 2Health News:Modern Healthcare Names DaVita One of the Best Places to Work 2Health News:Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments 2Health News:Cancer Patients in Southeastern Florida Now Benefiting From RapidArc(TM) Radiotherapy Treatments 3Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 3
... is a variation of Volk's ... 20mm provides 1.44x magnification and ... element. The lens is designed ... sits under the patients eyelid ...
... Direct Laser Lens affords the practitioner a ... of the eye. Utilizing a unique solid ... glass LaserWindow™ exterior, this special optical design ... profile fundus lenses. Available in Volk's exclusive ...
... The Volk PDT Laser Lens has been ... spot size onto the retina during photodynamic ... the optimum combination of field (137° FOV) ... carefully chosen after consultation with Dr. Peter ...
... diopter contact lens has been specifically designed ... lamp when traditional non-contact slit lamp lenses ... Plus delivers an outstanding 137° dynamic field ... pupils as small as 3mm.Evaluated by Harvey ...
Medicine Products: